ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1473

Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis

Peter M. Maloley1, Bryant R. England2, Harlan Sayles1, Geoffrey M. Thiele1, Michael J. Duryee3, Jeffrey Payne4 and Ted R. Mikuls5, 1University of Nebraska Medical Center, Omaha, NE, 2Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, 5Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: chemokines, cytokines and rheumatoid arthritis (RA), Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

 

Background/Purpose:  Cytokines and chemokines (CK) are central to RA pathogenesis, a fact underscored by the emergence of multiplex immunoassays for quantifying CK values in both research and clinical endeavors. Intrinsic factors to RA, namely rheumatoid factor (RF), may interfere with assay outcomes by nonspecifically binding detection analytes. Thus, we evaluated the performance of a commercially available multiplex platform using banked serum samples and assessed the impact of RF depletion on these measurements.

Methods:  Forty-five CK analytes were tested in a central laboratory using the Meso Scale Discovery V-PLEXTM  immunoassays and serum from 40 RA and 40 OA patients. True serum duplicates were tested for 20 RA and OA samples, while 20 additional samples from seropositive RA patients were depleted of RF using a commercial binder and compared to duplicates spiked with equal volumes of saline. Intra-assay coefficients of variation (CV) and intraclass correlation coefficients (ICC) were calculated for each analyte measured using true duplicates. The percent change in analyte concentrations were determined. Finally, rank sum tests were used to compare CK concentrations between RA and OA. Analytes were determined to be “high performers” if the CV was <10% and there was <15% change following RF depletion. Conversely, “low performers” were defined as those with a CV >20% or if RF depletion altered values >30%.

Results:  CVs and ICCs generated using true serum duplicates for the 45 analytes tested are shown in Table 1. Of the 45 analytes, 22 yielded CVs <10%; all but two were “high performers”. ICCs universally exceeded 0.85 with the exception of 7 analytes (6 were “low performers”). RF depletion altered CK values by <15% for 35 analytes with larger changes (>30%) seen only for IL-2 and TNF-α (Figure 1). IL6, IL8, IL10, TNFα, and TNFβ concentrations were increased in RA vs. OA (p<0.05); IL16 was decreased (p<0.05).

Conclusion:  In this study, a commercially available multiplex assay performed well in the context of RA. For most analytes, results were highly reproducible with minimal interference from RF. Additional testing will be needed to identify the source of variability observed for the analytes with higher CVs.

 


Table 1.  Intra-assay coefficient of variation (CV) using true serum duplicates

CV <10%

CV 10-20%

CV >20%

Eotaxin (0.98)

IL-27 (0.95)

GM-CSF (0.96)

Eotaxin-3 (0.98)

IL-12-23p40 (0.99)

IL-6 (1.00)

IFN-γ (0.99)

IL-17A-cyto (0.85)

IL-12-p70 (0.99)

IL-7 (0.97)

IL-10 (0.99)

IL-17A-F (0.47)

IL-13 (1.00)

IL-8-chem (0.99)

IL-17D (0.68)

IL-17B (0.60)

IL-15 (0.93)

IL-8-pro (1.00)

IL-2 (0.91)

IL-17C (0.71)

IL-16 (0.96)

MCP-1 (0.97)

IL-22 (0.96)

IL-1α (0.90)

IL-17A-TH17 (0.98)

MCP-4 (0.95)

IL-5 (0.96)

IL-3 (0.17)

IL-1RA (0.98)

MDC (0.89)

IP-10 (0.92)

IL-31 (0.96)

IL-1β (1.00)

MIP-1α (1.00)

MIP-3α (0.98)

IL-4 (0.99)

IL-21 (0.88)

MIP-1β (1.00)

TARC (0.96)

IL-9 (0.43)

IL-23 (0.97)

VEGF (0.98)

TNF-α (1.00)

TNF-β (0.95)

 

 

TSLP (0.49)

*Intraclass correlation coefficient (ICC) shown in parentheses

 

 


Figure 1.  Mean percent change in cytokine/chemokine analyte concentration following RF depletion.

*35 of 45 analytes exhibited <15% change; 8 analytes showed intermediate changes (15-30%) and two (IL-2 and TNF-α) demonstrated >30% change.


Disclosure: P. M. Maloley, None; B. R. England, None; H. Sayles, None; G. M. Thiele, None; M. J. Duryee, None; J. Payne, None; T. R. Mikuls, BMS, Ironwood, Horizon, 2,Pfizer, Inc., 5.

To cite this abstract in AMA style:

Maloley PM, England BR, Sayles H, Thiele GM, Duryee MJ, Payne J, Mikuls TR. Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/performance-of-the-meso-scale-multiplex-platform-in-the-assessment-of-serum-cytokines-chemokines-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-the-meso-scale-multiplex-platform-in-the-assessment-of-serum-cytokines-chemokines-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology